Daratumumab-Based Regimens Are Highly Effective and Well Tolerated in Relapsed or Refractory Multiple Myeloma Regardless of Patient Age: Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies
Haematologica - Italy
doi 10.3324/haematol.2019.217448
Full Text
Open PDFAbstract
Available in full text
Categories
Date
June 20, 2019
Authors
Publisher
Ferrata Storti Foundation (Haematologica)